Latest N30 Pharma Stories

2011-03-02 05:00:00

BOULDER, Colo., March 2, 2011 /PRNewswire/ -- N30 Pharmaceuticals, LLC (N30 Pharma) today announced it will present data at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011.

2010-09-08 05:00:00

BOULDER, Colo., Sept. 8 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR). N6022 is the first GSNOR inhibitor to be administered to human beings.

2010-08-02 07:00:00

BOULDER, Colo., Aug. 2 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration.

2010-05-11 07:00:00

BOULDER, Colo., May 11 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery and development of a new class of proprietary therapeutics that conserve endogenous, bioactive nitric oxide, announced today that it has completed a $10 million financing and expanded its Board of Directors. Joining the Company's Board of Directors will be Dr.

2009-04-06 10:18:00

BOULDER, Colo., April 6 /PRNewswire/ -- N30 Pharma today announced the formation of its Scientific Advisory Board, or SAB.

2009-03-23 07:00:00

BOULDER, Colo., March 23 /PRNewswire/ -- N30 Pharma (N30) today announced that Joseph Loscalzo, M.D., PhD., has joined the Board of Directors of the Company. Dr.

Word of the Day
  • The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.
The word 'logocentrism' is a blend of logo- +‎ centrism.